GRACEcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.

Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014


For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier. February 2014


For patients with wild type EGFR, meaning there is no EGFR mutation, drugs like Tarceva (erlotinib) can have a small benefit, but Dr. Joan Schiller wants research to do better. February 2014


Eighty percent of lung cancer patients have wild type EGFR, meaning there is no EGFR mutation. Dr. Joan Schiller of UT Southwestern Medical Center discusses a new drug in development that may help those patients. February 2014


The stigma of lung cancer can lead to shame, fear, and sub-optimal care. Dr. Joan Schiller wants us all to get past it, and she's leading the charge to make that happen. February 2014.


Does it make sense to do molecular testing on early stage lung cancer patients? Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute thinks it does in some settings. February 2014


Will the success seen for stage IV patients receiving targeted therapies translate into cure for stage III patients? Dr. Daniel Morgensztern of the Washington University School of Medicine talks about what research is ongoing to answer that question.


A current clinical trial (as of May 2014) asks if adding veliparib to chemo will increase progression free surival for late stage small cell lung cancer patients. For more information, visit clinicaltrials.gov and enter "ECOG 2511" in the search box.


Thanks to research, Dr. Daniel Morgensztern of the Washington University School of Medicine sees reason to be hopeful in the fight against lung cancer. February 2014

Direct download: GRACEcast-264_Lung-Video_IASLC_Morgensztern_LC_Fight_Optimism.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST

Research into small cell lung cancer may soon pay off in new treatments. Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute discusses new approaches that hold great promise. February 2014